After Short Bowel syndrome (SBS) designation, Napo Therapeutics gains another major Crofelemer’s orphan drug status approval for treatment of the very rare microvillary inclusion disease (MVID). The condition, characterized by untreatable neonatal secretory diarrhea, affects children from birth, condemning them to the risk of serious complications and to feed for life through parenteral therapy. Today, in the European Union 0.1 people out of 10,000 suffer from it.
In 2021 Napo Therapeutics, a European start-up based in Milan, was born in order to allow patients fighting against rare diseases to access therapies that finally make a difference in the quality of life. led by a team of professionals with long experience in the world of BiG Pharma who have chosen to dedicate themselves to the treatment of rare diseases and pathologies with a strong unmet medical needs. The EMA’s decision comes at the end of the Crofelemer evaluation process launched on May 19, 2022, with the submission by Napo Therapeutics of the application for designation of orphan drug status.
